Indications:
Gynaecological infections: including pelvic inflammatory diseases,
endometritis, cellulitis, vaginal cuff infections, tubo-ovarian abscess,
salpingitis.
Bone and joint infections: including osteomyelitis and septic arthritis.
Lower respiratory tract infections and lung abscess.
Intra-abdominal infections and peritonitis.
Septicemia and endocarditis.
Severe skin and soft tissue infections.
Severe dental infections.
Toxoplasmic encephalitis with in AIDS patients.

Dosage:

Adult dose: Life threatened infections 2400 mg- 2700 mg in 2,3,or 4 equal
divided doses.
Less complicated infections 1200 mg- 1800 mg in 3 or 4
equal divided doses .
Maximum dose /day 4800 mg.
Single I/M dose should not exceed than 600 mg.

Children dose: 20-40 mg/kg/day in 3 or 4 equal doses

Side effect:
1- Gastrointestinal
Abdominal pain, nausea, vomiting and diarrhea and
esophagitis with oral preparations.

2- Hypersensitivity reactions
Maculopapular rash and urticaria have been observed
during drug therapy .Generalized mild to moderate
morbilliform like skin rashes are the most frequently reported
reactions. Rare instances of erythema multiform, some
resembling Steven- Johnson syndrome have been associated
with clindamycin. A few cases of anaphylactoid reactions
have been reported.
3- Liver
Jaundice and abnormalities in liver function tests have
been observed during clindamycin therapy.
4- Skin and mucous membrane
Pruritis, vaginitis and rare instances of exfoliative and
vesiculobullous dermatitis have been reported.
5- Hematopoietic
Transient neutropenia (leucopenia) and eosinophilia have
been reported. Reports of agranulocytosis and thrombo-
cytopenia have been made. No direct etiologic relationship
to concurrent clindamycin therapy could be made in any
of foregoing.
6- Cardiovascular
Rare instances of cardiopulmonary arrest and hypotension
have been reported following too rapid I.V administration.
7- Local reaction
Local irritation, pain, abscess formation have been seen
with I.M injection. Thrombophlebitis has been reported
with I.V injection. These reactions can be minimized by
deep I.M injection and avoidance of indwelling intravenous
catheters.

Drug interaction:
The following drugs are physically incompatible with
clindamycin phosphate. Ampicillin, phenytoin sodium
barbiturates, aminophylline, calcium gluconate and
magnesium sulphate.
Clindamycin phosphate has been shown to be physically
and chemically compatible for at least 24 hours in dextrose
5% water and sodium chloride injection solution containing
the following antibiotics in usually administered concentrations:
Amikacin sulphate, aztereonam, cefamandole nafate, cefazolin
sodium, gentamycin sulphate, netilmicin sulphate,piperacillin
and tobramycin. The compatability and duration of stability
of drug admixtures will vary depending on concentration
and other conditions.
Pregnancy and lactation:
Do not administer Injections preserved with benzyl alcohol
to neonates, infants, pregnant women or nursing mothers.
Benzyl alcohol has been associated with serious adverse
events & death, particularly in pediatric patients. Injections
preservative free should be used in these populations.
Safety for use in pregnancy has not been established.
Clindamycin has been reported to appear in breast milk
in ranges from 0.7 to 3.8 ug / ml.

Packages:
Box containing 5 ampoules 300 mg/ 2 ml
Box containing 5 ampoules 600 mg/ 4 ml

Download AlfaClindamycin Flyer(PDF)